MedPath

Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Years of Age

Not Applicable
Completed
Conditions
Therapy
CIN2
Interventions
Procedure: Expectancy
Registration Number
NCT03177863
Lead Sponsor
Sahlgrenska University Hospital, Sweden
Brief Summary

In the Swedish organised cervical screening program precursors of cervical cancer are detected and treated. Most precursor lesions detected by screening heal spontaneously. Those who progress do it slowly. There are three levels from light; CIN1, moderate; CIN2 to severe; CIN3. Women with CIN3 are always treated, regardless of age, according to current clinical guidelines. Women with CIN2 who are below the age of 25 years are offered active expectance for up to two years because there is good evidence that they will spontaneously heal their lesions (regression) in 40-70% of the cases during that time.

Method of treatment is today an excisional procedure of the cervix most often by Large loop excision of the transformation zone (LLETZ/LEEP) Treatment increases the risk of premature birth in a future pregnancy. In 2015 about 1800 excisional procedures of the transformation zone of the cervix were performed in the Västra Götalands regionen (VGR) om Sweden. The average age of first-time mothers in Sweden is rising and in 2014 it was 29 years. Postponed childbearing raises the question whether it is possible to refrain from surgery even for the group of women over 25 years old, with proven CIN2. Existing studies suggest that cure of CIN2 in the age group of and above 25 takes place in the same extent as under 25 years of age.There is lack of evidence concerning clinical follow-up.

In a prospective multicenter clinical cohort study (observational study) with careful monitoring, the investigators will examine what proportion of CIN2 changes regress spontaneously within two years in women, 25-30 years old, and if human papillomavirus (HPV) type 16 may can be a marker for poor regression in this group. Instead of LLETZ, active expectance is offered to women this age with CIN2 in five gynecological clinics in VGR. The study protocol includes gynecologist visits every 6 months for two years, including cytology, colposcopy and directed biopsies of the cervix. Power calculation shows 160 women needs to be included, which is expected to occur within one year from the start.

Detailed Description

Available in Swedish

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
125
Inclusion Criteria
  • CIN 2
  • Written consent
Exclusion Criteria
  • CIN (any grade) not resolved
  • Former treatment of CIN
  • Immunomodulating medication
  • Pregnancy (at start of study)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Study cohortExpectancyHealthy women 25 - 30 years of age with CIN2 who consent to inclusion and with no former history of CIN (any grade). The "intervention" is expectancy with clinical visits every 6 months. Women will leave study cohort if found with total regression (no CIN) or CIN3
Primary Outcome Measures
NameTimeMethod
Proportion of regress24 months from date of visit when CIN2 was diagnosed

Proportion of women with CIN2 at inclusion who will regress to CIN1 or no evidence of disease

Secondary Outcome Measures
NameTimeMethod
Proportion of regress for women with HPV16Proportion of women with CIN2 at inclusion who will regress to CIN1 or no evidence of disease

Proportion of women with CIN2 and HPV 16 at inclusion who will regress to CIN1 or no evidence of disease

Trial Locations

Locations (5)

Kungshöjds gynekologmottagning

🇸🇪

Göteborg, Sweden

Södra Älvsborgs Sjukhus

🇸🇪

Borås, Sweden

Frölunda specialistsjukhus

🇸🇪

Göteborg, Sweden

Skaraborgs sjukhus, kvinnokliniken

🇸🇪

Skövde, Sweden

Norra Älvsborgs sjukhus, kvinnokliniken

🇸🇪

Trollhättan, Sweden

© Copyright 2025. All Rights Reserved by MedPath